CLYM
Climb Bio, Inc.
NASDAQ · Healthcare · Biotechnology · US
$9.33
−4.31%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$9.97
From 52W high−47.70%
Volume1.04M
Market cap$535.88M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataNov 4, 2026
Open
$9.97
From 52W high
−47.70%
Volume
1.04M
Market cap
$535.88M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−6.0x
P/E (TTM)
—
RSI (14)
37.4
MomentumView details →
1D Return
−4.31%
YTD Return
+132.25%
SummaryUpdated Jun 1, 2026
Climb Bio, Inc. (NASDAQ:CLYM) is a clinical-stage biotechnology company founded in 2018 and headquartered in Wilmington, Delaware. The company was originally incorporated as Eliem Therapeutics, Inc. before changing its name to Climb Bio in October 2024. Climb Bio focuses on developing innovative therapies for autoimmune-driven inflammatory diseases, with its lead drug candidate budoprutug currently in clinical development for multiple autoimmune conditions including systemic lupus erythematosus and lupus nephritis.
Similar companies
Latest newsMore news →
Climb Bio announced that members of its executive team will participate in the upcoming Guggenheim Partners LLC 3rd Annual Healthcare Innovation Conference.3d agoClimb Bio, Inc. presented initial Phase 2 PrisMN data showing that 200 mg of budoprutug demonstrated B-cell depletion, PLA2R antibody reduction, and immunologic remission at 12 weeks in patients with primary membranous nephropathy.11d agoClimb Bio and Beijing Mabworks Biotech announced clinical data for CLYM116/MIL116 showing more than 90% free APRIL suppression sustained through 12 weeks and an approximately 70% reduction in Gd-IgA1 at 12 weeks.12d ago